Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey-Reference-Cited by-同舟云学术

Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey

Published:2021-01-16 Issue:1 Volume:42 Page:87-94
ISSN:0172-8172
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Kavrul Kayaalp Gülsah^ORCID,Sozeri Betül^ORCID,Sönmez Hafize Emine^ORCID,Demir Ferhat^ORCID,Cakan Mustafa^ORCID,Oztürk Kübra^ORCID,Karadag Serife Gül^ORCID,Otar Yener Gülcin^ORCID,Ozdel Semanur^ORCID,Baglan Esra^ORCID,Celikel Elif^ORCID,Sahin Nihal^ORCID,Gezgin Yildirim Deniz^ORCID,Eker Omeroglu Rukiye^ORCID,Aktay Ayaz Nuray^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s00296-020-04776-1.pdf

Reference45 articles.

1. Ben-Chetrit E, Touitou I (2009) Familial mediterranean Fever in the world. Arthritis Rheum 61(10):1447–1453

2. Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10(3):135–147

3. Gül A (2014) Treatment of familial Mediterranean fever: colchicine and beyond. Isr Med Assoc J 16(5):281–284

4. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41(2):265–271

5. Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S et al (2017) Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind. Placebo-Controlled Trial Arthritis Rheumatol 69(4):854–862

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience;Pediatric Rheumatology;2023-11-23

2. Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever;Rheumatology;2023-03-24

3. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever;Rheumatology International;2022-09-01

4. Colchicine resistance: Associated factors and its effect on health‐related quality of life in patients with familial Mediterranean fever;International Journal of Rheumatic Diseases;2022-07-29